Breast Surgery Practice Questions

Q: Which of the following statements is false regarding fibroadenoma?

It is not encapsulated.. ### Explanation **Fibroadenoma** is the most common benign tumor of the female breast, often referred to as the **"Breast Mouse"** due to its high mobility within the breast tissue. #### 1. Why Option D is the Correct (False) Statement Fibroadenoma is a **true benign neoplasm** that is **well-encapsulated**. On gross examination, it appears as a firm, lobulated, greyish-white mass with a distinct capsule that allows it to be easily "shelled out" during surgical excision (enucleation). Stating that it is not encapsulated is pathologically incorrect. #### 2. Analysis of Other Options * **Option A (Benign tumor):** This is true. It arises from the terminal duct lobular unit and involves both epithelial and stromal proliferation. It has no malignant potential in its simple form. * **Option B (Typically painless):** This is true. Fibroadenomas usually present as a painless, firm, and discrete lump. Pain is rare unless the tumor undergoes rapid growth (e.g., during pregnancy). * **Option C (Commonly occurs in young females):** This is true. The peak incidence is between **15–35 years** of age. It is considered an aberration of normal development and involution (ANDI). #### 3. NEET-PG High-Yield Clinical Pearls * **Mobility:** Its hallmark is extreme mobility within the breast parenchyma. * **Mammography:** Often shows a well-defined mass; in older women, it may show characteristic **"Popcorn calcification"** (due to involution). * **USG:** Usually shows a hypoechoic, well-circumscribed, oval mass with a horizontal orientation (wider than tall). * **Management:** Conservative management is preferred for small lesions ( 5 cm in diameter or >500g in weight.

Q: All of the following statements about lobular carcinoma of the breast are true EXCEPT:

Easily detectable in mammography. **Explanation:** Invasive Lobular Carcinoma (ILC) is the second most common type of breast cancer. The correct answer is **Option A** because ILC is notoriously **difficult to detect on mammography**, making the statement "Easily detectable" false. **1. Why Option A is the correct (False) statement:** ILC cells typically lack the adhesion molecule **E-cadherin**. This leads to a characteristic "single-file" (Indian file) growth pattern that infiltrates the stroma without forming a dense, discrete tumor mass or causing significant desmoplastic reactions. Consequently, it often does not produce a distinct opacity or microcalcifications on mammography, frequently resulting in false-negative findings. **2. Analysis of other options:** * **Option B (30% bilateral):** ILC has a much higher propensity for multicentricity (multiple foci in the same breast) and bilaterality (up to 30%) compared to Invasive Ductal Carcinoma (IDC). * **Option C (Lobectomy is less preferred):** Because ILC is often diffuse, multifocal, and difficult to marginate clinically or radiologically, breast-conserving surgery (like lobectomy/wide local excision) is more challenging and carries a higher risk of positive margins compared to IDC. * **Option D (Difficult to detect in mammography):** This is a true clinical characteristic of ILC, as explained above. **Clinical Pearls for NEET-PG:** * **Molecular Hallmark:** Loss of **E-cadherin** expression (CDH1 gene mutation). * **Imaging Choice:** **MRI** is the most sensitive imaging modality for ILC to assess the true extent of the disease. * **Metastatic Pattern:** Unlike IDC, ILC tends to spread to unusual sites like the peritoneum, retroperitoneum, leptomeninges, and gastrointestinal tract. * **Histology:** Cells are small, uniform, and arranged in a linear "Indian file" pattern.

Q: What is the percentage of malignancy in duct ectasia?

No risk. **Explanation:** **Duct ectasia** (also known as periductal mastitis) is a benign inflammatory condition characterized by the dilation of large retroareolar ducts, which become filled with inspissated secretions. 1. **Why "No risk" is correct:** Duct ectasia is purely an **inflammatory and obstructive process**, not a proliferative one. Unlike conditions such as atypical ductal hyperplasia (ADH) or papillomatosis, duct ectasia does not involve abnormal cellular proliferation or genetic mutations that lead to carcinogenesis. Therefore, it carries **zero increased risk** for the development of breast cancer. It is classified under "Non-proliferative lesions" of the breast. 2. **Why other options are incorrect:** * **5% and 10%:** These figures are often associated with the risk of malignancy in other lesions like solitary intraductal papillomas or certain types of proliferative disease without atypia, but they do not apply to duct ectasia. * **1.2%:** This is a distractor. While some benign lesions have a very slight relative risk (1.2 to 1.5x), duct ectasia remains at a relative risk of 1.0 (baseline). **Clinical Pearls for NEET-PG:** * **Clinical Presentation:** Typically seen in perimenopausal women; presents with **slit-like nipple retraction** and thick, "cheesy" or multicolored (green/black) nipple discharge. * **Pathology:** Characterized by plasma cell infiltration (hence the name **Plasma Cell Mastitis**). * **Mammography:** May show "ring-like" or "tubular" calcifications (secretory calcifications). * **Management:** Reassurance is key. If symptoms are bothersome, **Hadfield’s operation** (total duct excision) is the surgical treatment of choice.

Q: What is the role of neoadjuvant chemotherapy in breast carcinoma patients?

To shrink the tumor to enable breast-conserving therapy. ### Explanation **Neoadjuvant Chemotherapy (NACT)** refers to the administration of systemic chemotherapy before definitive local surgical treatment. **1. Why Option B is Correct:** The primary surgical objective of NACT in breast cancer is **downstaging**. By shrinking a large primary tumor, NACT can convert a patient who was initially a candidate only for a Total Mastectomy into a candidate for **Breast Conserving Surgery (BCS)**. It also helps in downstaging involved axillary lymph nodes, potentially avoiding a morbid axillary lymph node dissection (ALND). **2. Why Other Options are Incorrect:** * **Option A & C:** While NACT treats micrometastases early, it is not a "cure" for established distant metastasis (Stage IV), nor is its primary definition "limiting" metastasis; its role is local downstaging for better surgical outcomes. * **Option D:** Symptomatic relief is the goal of *palliative* chemotherapy. NACT is part of a *curative* intent protocol. **3. NEET-PG High-Yield Pearls:** * **Indications for NACT:** Locally Advanced Breast Cancer (LABC), inflammatory breast cancer, or large tumors where the tumor-to-breast ratio precludes BCS. * **Pathological Complete Response (pCR):** The most important prognostic marker after NACT. It is defined as the absence of invasive cancer in the breast and axilla at the time of surgery. * **Molecular Subtypes:** Triple-negative (TNBC) and HER2-positive breast cancers show the highest rates of pCR with NACT. * **Monitoring:** The clinical response to NACT is monitored via physical exam and imaging (MRI is the most sensitive). If the tumor progresses during NACT, surgery should be performed immediately.

Q: What is the best diagnostic method for a breast lump?

Biopsy. **Explanation:** The gold standard for diagnosing a breast lump is the **Triple Assessment**, which includes clinical examination, imaging, and pathological confirmation. Among the options provided, **Biopsy** is the best diagnostic method because it provides a definitive tissue diagnosis. **Why Biopsy is the Correct Answer:** A biopsy (specifically Core Needle Biopsy) allows for the assessment of tissue architecture, which is essential to differentiate between *in situ* and invasive carcinoma. It also provides tissue for immunohistochemistry (ER, PR, and HER2/neu status), which is critical for planning management. While FNAC provides cellular details, a biopsy is superior as it eliminates the high false-negative rates associated with cytology. **Analysis of Incorrect Options:** * **Ultrasound (USG):** This is the investigation of choice for women 35 years. It can suggest malignancy (e.g., microcalcifications, spiculation) but cannot provide a definitive diagnosis. * **FNAC:** Though quick and inexpensive, it cannot distinguish between invasive and non-invasive (DCIS) cancer because it lacks architectural context. It is increasingly being replaced by Core Needle Biopsy in modern protocols. **High-Yield Clinical Pearls for NEET-PG:** * **Investigation of choice for 35 years:** Mammography. * **Best/Gold Standard Diagnostic:** Core Needle Biopsy (CNB). * **Triple Assessment:** If all three (Clinical, Imaging, Pathological) are concordant, the diagnostic accuracy is >99%.

Q: A 45-year-old female presents to the OPD with a complaint of a lump in the right breast. On examination, a 5 x 5 cm lump is palpated. Axillary lymph nodes are found to be normal in size, consistency, and texture. What is the MOST likely diagnosis?

Angiosarcoma. **Explanation:** The clinical presentation of a large breast lump (**5 x 5 cm**) in the absence of axillary lymphadenopathy is a classic diagnostic clue for **Angiosarcoma** of the breast. **1. Why Angiosarcoma is correct:** Angiosarcoma is a rare, highly aggressive malignant tumor of the vascular endothelium. Unlike epithelial breast cancers (like ductal or lobular carcinoma), angiosarcomas are **mesenchymal** in origin. A hallmark of mesenchymal tumors (sarcomas) is that they primarily spread via the **hematogenous route** (bloodstream) rather than the lymphatic system. Therefore, even with a large primary tumor size, the axillary lymph nodes typically remain clinically normal. **2. Why other options are incorrect:** * **Ductal Carcinoma (Option A) & Lobular Carcinoma (Option D):** These are epithelial tumors (carcinomas). They characteristically spread via the **lymphatic system** first. A 5 cm tumor (Stage T3) would highly likely be associated with reactive or metastatic axillary lymphadenopathy. * **Comedo Carcinoma (Option B):** This is a high-grade subtype of Ductal Carcinoma In Situ (DCIS). While it can be aggressive, it is an epithelial lesion and does not typically present as a large isolated mass without lymphatic involvement if it has become invasive. **3. NEET-PG High-Yield Pearls:** * **Sarcomas vs. Carcinomas:** Remember the rule—Sarcomas spread via blood (except for exceptions like Rhabdomyosarcoma or Synovial sarcoma); Carcinomas spread via lymphatics (except for Renal Cell, HCC, and Follicular Thyroid CA). * **Stewart-Treves Syndrome:** This is a specific type of angiosarcoma that develops in a limb affected by chronic lymphedema (classically after a radical mastectomy). * **Primary vs. Secondary:** Primary angiosarcoma occurs sporadically in younger women (30-50 years), while secondary angiosarcoma is often a late complication of **radiation therapy**.

Q: A female patient underwent mastectomy for carcinoma of the breast. A few days after surgery, she experienced burning pain along the medial aspect of her arm. What is the most likely cause of this pain?

Intercostobrachial neuralgia. **Explanation:** The correct answer is **Intercostobrachial neuralgia**. This is a common complication following mastectomy or axillary lymph node dissection (ALND), occurring in up to 20-50% of patients. **1. Why Intercostobrachial Neuralgia is Correct:** The **intercostobrachial nerve (ICBN)** is the lateral cutaneous branch of the second intercostal nerve (T2). It provides sensory innervation to the **skin of the axilla and the medial aspect of the upper arm**. During mastectomy or axillary clearance, this nerve is frequently stretched, compressed, or severed. Injury leads to neuropathic symptoms, typically described as **burning, tingling, or lancinating pain** localized specifically to the medial arm and axilla. **2. Analysis of Incorrect Options:** * **Phantom breast pain:** This refers to the sensation of pain in the tissue that has been removed (the breast itself). While common after mastectomy, it does not localize to the medial arm. * **Neuroma pain:** This occurs due to disorganized axonal regrowth at the site of a nerve transection. While it causes neuropathic pain, it usually presents later (weeks to months) and is localized to a specific trigger point or the surgical scar rather than a dermatomal distribution like the medial arm. * **Other nerve injury pain:** While nerves like the long thoracic or thoracodorsal can be injured, they are primarily **motor nerves**. Injury to these would result in functional deficits (e.g., winged scapula) rather than sensory burning pain in the arm. **Clinical Pearls for NEET-PG:** * **Post-Mastectomy Pain Syndrome (PMPS):** A chronic neuropathic pain condition lasting >3 months. The ICBN is the most commonly implicated nerve. * **Nerve Origin:** ICBN originates from the **T2 spinal level**. * **Management:** Initial treatment involves neuropathic agents like Gabapentin, Pregabalin, or Amitriptyline. Regional blocks (e.g., Paravertebral block) can be used for prevention.

Question 1

Which of the following statements is false regarding fibroadenoma?

Accepted Answer

It is not encapsulated.

Answer

It is a benign tumor.

Answer

It is typically painless.

Answer

It commonly occurs in young females.

Question 2

Which of the following statements about DCIS of the breast is true?

Accepted Answer

Rarely, DCIS can produce nipple discharge.

Answer

DCIS is a benign proliferation of epithelial cells.

Answer

DCIS involves only specific sectors of the breast.

Answer

DCIS is almost always detected histologically.

Question 3

True regarding breast carcinoma is:

Accepted Answer

Commoner in nulliparous women

Answer

Occurs most commonly in the upper outer quadrant

Answer

Early menarche and late menopause predispose for breast malignancy

Answer

Unrelated to family history of breast cancer

Question 4

All of the following statements about lobular carcinoma of the breast are true EXCEPT:

Accepted Answer

Easily detectable in mammography

Answer

30% bilateral

Answer

Lobectomy is less preferred

Answer

Difficult to detect in mammography.

Question 5

What is the percentage of malignancy in duct ectasia?

Accepted Answer

No risk

Answer

5%

Answer

1.2%

Answer

10%

Question 6

What is the role of neoadjuvant chemotherapy in breast carcinoma patients?

Accepted Answer

To shrink the tumor to enable breast-conserving therapy

Answer

Curing distant metastasis

Answer

Limiting metastasis

Answer

Symptomatic relief

Question 7

What is the best diagnostic method for a breast lump?

Accepted Answer

Biopsy

Answer

Ultrasound (USG)

Answer

Mammogram

Answer

Fine Needle Aspiration Cytology (FNAC)

Question 8

Breast conservation surgery is indicated in which of the following conditions?

Accepted Answer

T4b breast tumor

Answer

T1 breast tumor

Answer

Multicentric tumor

Answer

Extensive in situ cancer

Question 9

A 45-year-old female presents to the OPD with a complaint of a lump in the right breast. On examination, a 5 x 5 cm lump is palpated. Axillary lymph nodes are found to be normal in size, consistency, and texture. What is the MOST likely diagnosis?

Accepted Answer

Angiosarcoma

Answer

Ductal carcinoma

Answer

Comedo carcinoma

Answer

Lobular carcinoma

Question 10

A female patient underwent mastectomy for carcinoma of the breast. A few days after surgery, she experienced burning pain along the medial aspect of her arm. What is the most likely cause of this pain?

Accepted Answer

Intercostobrachial neuralgia

Answer

Phantom breast pain

Answer

Neuroma pain

Answer

Other nerve injury pain

Breast Surgery — MCQs

Breast Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?